XOMA (XOMA) to Release Quarterly Earnings on Friday

XOMA (NASDAQ:XOMA) is projected to release its earnings data before the market opens on Friday, March 14th. Analysts expect XOMA to post earnings of ($0.29) per share and revenue of $8.75 million for the quarter.

XOMA Stock Performance

Shares of XOMA stock opened at $21.16 on Thursday. The company has a market cap of $249.33 million, a P/E ratio of -6.08 and a beta of 1.00. The firm has a fifty day moving average price of $25.20 and a 200 day moving average price of $27.59. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a 12 month low of $19.92 and a 12 month high of $35.00.

Analysts Set New Price Targets

Several brokerages have recently weighed in on XOMA. StockNews.com lowered XOMA from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th. HC Wainwright reduced their price objective on shares of XOMA from $123.00 to $104.00 and set a “buy” rating for the company in a research report on Monday, February 3rd.

Insider Buying and Selling

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 7.20% of the stock is currently owned by company insiders.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.